Nuvilex (NASDAQ:PMCB) Trading 0.2% Higher – Here’s Why

Nuvilex Inc. (NASDAQ:PMCB)’s stock price was up 0.2% during mid-day trading on Friday . The company traded as high as $0.5712 and last traded at $0.5510. Approximately 131,483 shares were traded during trading, an increase of 0% from the average session volume of 131,438 shares. The stock had previously closed at $0.55.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Nuvilex from a “sell (d)” rating to a “sell (e+)” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Nuvilex Stock Performance

The company has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.72. The firm has a market capitalization of $5.92 million, a P/E ratio of -0.18 and a beta of 0.57.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.